Drug therapies for HIV-related metabolic disorders

References

• Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853–860.
   PubMed Web of Science ®Google Scholar
• Silverberg MJ, Leyden W, Horberg MA, et al. Older age and the response to and tolerability of antiretroviral therapy. Arch Intern Med. 2007;167:684–691.
   PubMed Web of Science ®Google Scholar
• Currier JS, Taylor A, Boyd F, et al. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr. 2003;33:506–512.
   PubMed Web of Science ®Google Scholar
• Barbaro G. Highly active antiretroviral therapy-associated metabolic syndrome: pathogenesis and cardiovascular risk. Am J Ther. 2006;13:248–260.
   PubMed Web of Science ®Google Scholar
• Paik IJ, Kotler DP. The prevalence and pathogenesis of diabetes mellitus in treated HIV-infection. Best Pract Res Clin Endocrinol Metab. 2011;25:469–478.
   PubMed Web of Science ®Google Scholar
• Obel N, Thomsen HF, Kronborg G, et al. Ischemic heart disease in HIV-infected and HIV-uninfected individuals: a population-based cohort study. Clin Infect Dis. 2007;44:1625–1631.
   PubMed Web of Science ®Google Scholar
• Michael L, Green MD, MSc J. Evaluation and management of dyslipidemia in patients with HIV infection. Gen Intern Med. 2002;17:797–810.
   PubMed Web of Science ®Google Scholar
• Hsue PY, Lo JC, Franklin A, et al. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation. 2004;109:1603–1608.
   PubMed Web of Science ®Google Scholar
• Deeks SG. HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med. 2011;62:141–155.
   PubMed Web of Science ®Google Scholar
• Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008;5:e203.
   PubMed Web of Science ®Google Scholar
• Nix LM, Tien PC. Metabolic syndrome, diabetes, and cardiovascular risk in HIV. Curr HIV/AIDS Rep. 2014;11:271–278.
   PubMed Web of Science ®Google Scholar
• Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med. 2005;352:48–62.
   PubMed Web of Science ®Google Scholar
• Young J, Weber R, Rickenbach M, et al. Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study. Antivir Ther. 2005;10:585–591.
   PubMed Web of Science ®Google Scholar
• Cahn PE, Gatell JM, Squires K, et al. Atazanavir–a once-daily HIV protease inhibitor that does not cause dyslipidemia in newly treated patients: results from two randomized clinical trials. J Int Assoc Physicians AIDS Care (Chic). 2004;3:92–98.
   PubMedGoogle Scholar
• European AIDS Clinical Society. EACS European Guidelines for treatment of HIV infected adults in Europe. [ cited 2016 Mar 31]. Available from: http://www.eacsociety.org/Guidelines.aspx.
   Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. [cited 2016 Mar 27]. Available from: http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf.
   Google Scholar
• Grupo de expertos del Grupo de Estudio sobre Alteraciones Metabólicas (GEAM), de la Secretaría del Plan Nacional sobre el Sida (SPNS) y del Grupo de Estudio de Sida (GeSIDA). Consensus statement on metabolic disorders and cardiovascular risks in patients with human immunodeficiency virus. Enferm Infecc Microbiol Clin. 2015;33:40.e1–40.e16.
   Google Scholar
• Aberg JA. Lipid management in patients who have HIV and are receiving HIV therapy. Endocrinol Metab Clin North Am. 2009;38:207–222.
   PubMed Web of Science ®Google Scholar
• Calza L, Manfredi R, Colangeli V, et al. Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia. AIDS. 2005;19:1051–1058.
   PubMed Web of Science ®Google Scholar
• Van Der Valk M, Friis-Møller N, Sabin C. Effect of interventions to improve dyslipidaemia. Paper presented at the 8th International Congress on Drug Therapy in HIV Infection; Nov 12–16; Glasgow, UK; 2006.
   Google Scholar
• Monteiro P, Baker D, Bloch M, et al. Rosuvastatin vs. Protease inhibitor switch for hypercholesterolaemia: a randomised trial - the statin or switch (sos) study. Presented at The annual Conference on Retroviruses and Opportunistic Infections; Seattle; 2015. Poster #2090723.
   Google Scholar
• Kaplan RC, Kingsley LA, Sharrett AR, et al. Ten-year predicted coronary heart disease risk in HIV-infected men and women. Clin Infect Dis. 2007;45:1074–1081.
   PubMed Web of Science ®Google Scholar
• Chauvin B, Drouot S, Barrail-Tran A, et al. Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors. Clin Pharmacokinet. 2013;52:815–831.
   PubMed Web of Science ®Google Scholar
• Penzak SR, Chuck SK. Management of protease inhibitor-associated hyperlipidemia. Am J Cardiovasc Drugs. 2002;2:91–106.
   PubMedGoogle Scholar
• Gerber JG, Rosenkranz SL, Fichtenbaum CJ, et al.; AIDS Clinical Trials Group A5108 Team. Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study. J Acquir Immune Defic Syndr. 2005;39:307–312.
   PubMed Web of Science ®Google Scholar
• Soler A, Deig E, Guil J. Effectiveness and tolerance of atorvastatin for antiretroviral therapy-secondary dyslipemia. Med Clin (Barc). 2006;127:250–252.
   PubMed Web of Science ®Google Scholar
• Calza L, Manfredi R, Colangeli V, et al. Rosuvastatin, pravastatin, and atorvastatin for the treatment of hypercholesterolaemia in HIV-infected patients receiving protease inhibitors. Curr HIV Res. 2008;6:572–578.
   PubMed Web of Science ®Google Scholar
• Silverberg MJ, Leyden W, Hurley L, et al. Response to newly prescribed lipid-lowering therapy in patients with and without HIV infection. Ann Intern Med. 2009;150:301–313.
   PubMed Web of Science ®Google Scholar
• Pham PA, La Porte CJ, Lee LS, et al. Differential effects of tipranavir plus ritonavir on atorvastatin or rosuvastatin pharmacokinetics in healthy volunteers. Antimicrob Agents Chemother. 2009;53:4385–4392.
   PubMed Web of Science ®Google Scholar
• Castro JG, Gutierrez L. Rhabdomyolysis with acute renal failure probably related to the interaction of atorvastatin and delavirdine. Am J Med. 2002;112:505.
   PubMed Web of Science ®Google Scholar
• Mah Ming JB, Gill MJ. Case report: drug-induced rhabdomyolysis after concomitant use of clarithromycin, atorvastatin, and lopinavir/ritonavir in a patient with HIV. AIDS Patient Care STD. 2003;17:207–210.
   PubMed Web of Science ®Google Scholar
• Calza L, Manfredi R, Chiodo F. Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients. J Antimicrob Chemother. 2004;53:10–14.
   PubMed Web of Science ®Google Scholar
• Jacobson TA. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am J Cardiol. 2004;94:1140–1146.
   PubMed Web of Science ®Google Scholar
• Bonnet F, Aurillac-Lavignolle V, Breilh D, et al. Pravastatin in HIV-infected patients treated with protease inhibitors: a placebo-controlled randomized study. HIV Clin Trials. 2007;8:53–60.
   PubMed Web of Science ®Google Scholar
• Aberg JA, Zackin RA, Brobst SW, et al. A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS clinical trials group study 5087. AIDS Res Hum Retroviruses. 2005;21:757–767.
   PubMed Web of Science ®Google Scholar
• Calza L, Colangeli V, Manfredi R, et al. Rosuvastatin for the treatment of hyperlipidaemia in HIV-infected patients receiving protease inhibitors: a pilot study. AIDS. 2005;19:1103–1105.
   PubMed Web of Science ®Google Scholar
• Kiser JJ, Gerber JG, Predhomme JA, et al. Drug/Drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers. J Acquir Immune Defic Syndr. 2008;47:570–578.
   PubMed Web of Science ®Google Scholar
• Van Der Lee M, Sankatsing R, Schippers E, et al. Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients. Antivir Ther. 2007;12:1127–1132.
   PubMed Web of Science ®Google Scholar
• Aslangul E, Assoumou L, Bittar R. Rosuvastatin versus pravastatin in dyslipidemic HIV-1-infected patients receiving protease inhibitors: a randomized trial. AIDS. 2010;24:77–83.
   PubMed Web of Science ®Google Scholar
• Calza L, Manfredi R, Chiodo F. Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART. AIDS. 2003;17:851–859.
   PubMed Web of Science ®Google Scholar
• Dubé MP, Stein JH, Aberg JA, et al.; for the Adult AIDS Clinical Trials Group Cardiovascular Subcommittee. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)–infected adults receiving antiretroviral therapy: recommendations of the HIV medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis. 2003;37:613–627.
   PubMed Web of Science ®Google Scholar
• Chow D, Chen H, Glesby MJ. Short-term ezetimibe is well tolerated and effective in combination with statin therapy to treat elevated LDL cholesterol in HIV-infected patients. AIDS. 2009;23:2133–2141.
   PubMed Web of Science ®Google Scholar
• Sponseller C, Morgan R, Campbell S, et al. Pitavastatin 4 mg provides greater LDL-C reduction compared to pravastatin 40 mg over 12 weeks of treatment in HIV-infected adults with dyslipidemia. Poster presented at the 20th Conference on Retroviruses & Opportunistic Infections; 2013 Mar 3–6; Atlanta, GA.
   Google Scholar
• Negredo E, Moltó J, Puig J, et al. Ezetimibe, a promising lipid-lowering agent for the treatment of dyslipidaemia in HIV-infected patients with poor response to statins. AIDS. 2006;20:2159–2164.
   PubMed Web of Science ®Google Scholar
• Coll B, Aragonés G, Parra S, et al. Ezetimibe effectively decreases LDL-cholesterol in HIV-infected patients. AIDS. 2006;20:1675–1677.
   PubMed Web of Science ®Google Scholar
• Wohl DA, Waters D, Simpson RJ Jr, et al. Ezetimibe alone reduces low-density lipoprotein cholesterol in HIV-infected patients receiving combination antiretroviral therapy. Clin Infect Dis. 2008;47:1105–1108.
   PubMed Web of Science ®Google Scholar
• Da Cunha J, Maselli LM, Stern AC, et al. Impact of antiretroviral therapy on lipid metabolism of human immunodeficiency virus-infected patients: old and new drugs. World J Virol. 2015;4:56–77.
   PubMedGoogle Scholar
• Berg-Wolf MV, Klibanov OM, Gaughan JP, et al. Ezetimibe combined with low-dose statin effectively lowers LDL in protease inhibitor treated patients. AIDS Patient Care STDS. 2008;22:483–488.
   PubMed Web of Science ®Google Scholar
• Bennett MT, Johns KW, Bondy GP. Ezetimibe is effective when added to maximally tolerated lipid lowering therapy in patients with HIV. Lipids Health Dis. 2007;6:15.
   PubMed Web of Science ®Google Scholar
• Chastain LM, Bain AM, Edwards KL, et al. A retrospective study of the lipid-lowering efficacy and safety of ezetimibe added to hydroxy methylglutaryl coenzyme A reductase therapy in HIV-infected patients with hyperlipidemia. J Clin Lipidol. 2007;1:634–639.
   PubMed Web of Science ®Google Scholar
• Grandi AM, Nicolini E, Rizzi L, et al. Dyslipidemia in HIV-positive patients: a randomized, controlled, prospective study on ezetimibe+fenofibrate versus pravastatin monotherapy. J Int AIDS Soc. 2014;17:19004.
   PubMed Web of Science ®Google Scholar
• Gerber MT, Mondy KE, Yarasheski KE, et al. Niacin in HIV-infected individuals with hyperlipidemia receiving potent antiretroviral therapy. Clin Infect Dis. 2004;39:419–425.
   PubMed Web of Science ®Google Scholar
• Dubé MP, Wu JW, Aberg JA, et al. Safety and efficacy of extended-release niacin for the treatment of dyslipidaemia in patients with HIV infection: AIDS Clinical Trials Group Study A5148. Antivir Ther. 2006;11:1081–1089.
   PubMed Web of Science ®Google Scholar
• Souza SA, Chow DC, Walsh EJ, et al. Pilot study on the safety and tolerability of extended release niacin for HIV-infected patients with hypertriglyceridemia. Hawaii Med J. 2010;69:122–125.
   PubMedGoogle Scholar
• Rader DJ. Effects of nonstatin lipid drug therapy on high-density lipoprotein metabolism. Am J Cardiol. 2003;91:18E–23E.
   PubMed Web of Science ®Google Scholar
• National Cholesterol Education Program N. Third report of the expert panel on detection, evaluation and treatment of high blood cholesterol in adults (adult treatment panel III). 2008 [cited 2008 May 23]. Available from: http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3_rpt.htm.
   Google Scholar
• Lundgren JD, Battegay M, Behrens G, et al. European AIDS clinical society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. HIV Med. 2008;9:72–81.
   PubMed Web of Science ®Google Scholar
• Badiou S. Fenofibrate improves the atherogenic lipid profile and enhances LDL resistance to oxidation in HIV-positive adults. Atherosclerosis. 2004;172:273–279.
   PubMed Web of Science ®Google Scholar
• Jellinger PS, Smith DA, Mehta AE, et al. The AACE task force for management of dyslipidemia and prevention of atherosclerosis. American Association of Clinical Endocrinologists´ guidelines for management of dyslipidemia and prevention of atherosclerosis. Endocrine Practice. 2012;18(supp 1):1–78.
   PubMedGoogle Scholar
• Caramelli B, De Bernoche CY, Sartori AM, et al. Hyperlipidemia related to the use of HIV-protease inhibitors: natural history and results of treatment with fenofibrate. Braz J Infect Dis. 2001;5:332–338.
   PubMedGoogle Scholar
• Palacios R. Efficacy and safety of fenofibrate for the treatment of hypertriglyceridemia associated with antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;31:251–253.
   PubMed Web of Science ®Google Scholar
• Rao A, D’Amico S, Balasubramanyam A, et al. Fenofibrate is effective in treating hypertriglyceridemia associated with HIV lipodystrophy. Am J Med Sci. 2004;327:315–318.
   PubMed Web of Science ®Google Scholar
• Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the diabetes atherosclerosis intervention study, a randomised study. Lancet. 2001;357:905–910.
   PubMed Web of Science ®Google Scholar
• Samineni D, Fichtenbaum CJ. Fenofibrate in the treatment of dyslipidemia associated with HIV infection. Expert Opin Drug Metab Toxicol. 2010;6:995–1004.
   PubMed Web of Science ®Google Scholar
• Mastroianni CM, d’Ettorre G, Forcina G, et al. Rhabdomyolysis after cerivastatin-gemfibrozil therapy in an HIV-infected patient with protease inhibitor–related hyperlipidemia. AIDS. 2001;15:820–821.
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Davidson MH. Possible differences between fibrates in pharmacokinetic interactions with statins. Arch Intern Med. 2003;163:2394–2395.
   PubMedGoogle Scholar
• Rosenson RS. Current overview of statin-induced myopathy. Am J Med. 2004;116:408–416.
   PubMed Web of Science ®Google Scholar
• Fichtenbaum CJ, Yeh TM, Evans SR, et al. Treatment with pravastatin and fenofibrate improves atherogenic lipid profiles but not inflammatory markers in ACTG 5087. J Clin Lipidol. 2010;4:279–287.
   PubMed Web of Science ®Google Scholar
• Balasubramanyam A, Coraza I, Smith EO, et al. Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of “heart positive,” a randomized, controlled trial. J Clin Endocrinol Metab. 2011;96:2236–2247.
   PubMed Web of Science ®Google Scholar
• Gerber JG, Kitch DW, Fichtenbaum CJ, et al. Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186. J Acquir Immune Defic Syndr. 2008;47(4):59–66.
   Web of Science ®Google Scholar
• Visnegarwala F, Maldonado M, Sajja P, et al. Lipid lowering effects of statins and fibrates in the management of HIV dyslipidemias associated with antiretroviral therapy in HIV clinical practice. J Infect. 2004;49:283–290.
   PubMed Web of Science ®Google Scholar
• Miller J, Brown D, Amin J, et al. A randomized, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridaemia. AIDS. 2002;16:2195–2200.
   PubMed Web of Science ®Google Scholar
• Kris-Etherton PM, Harris WS, Appel LJ, American Heart Association. Nutrition Committee. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation. 2002;106:2747.
   PubMed Web of Science ®Google Scholar
• Metroka CE, Truong P, Gotto AM Jr. Treatment of HIV-associated dyslipidemia: a role for omega-3 fatty acids. AIDS Read. 2007;17:362-4, 367-73.
   PubMedGoogle Scholar
• Wohl DA, Tien H-C, Busby M, et al. Randomized study of the safety and efficacy of fish oil (omega-3 fatty acid) supplementation with dietary and exercise counseling for the treatment of antiretroviral therapy-associated hypertriglyceridemia. Clin Infect Dis. 2005;41:1498–1504.
   PubMed Web of Science ®Google Scholar
• De Truchis P, Kirstetter M, Perier A, et al. Reduction in triglyceride level with N-3 polyunsaturated fatty acids in HIV-infected patients taking potent antiretroviral therapy: a randomized prospective study. J Acquir Immune Defic Syndr. 2007;44:278–285.
   PubMed Web of Science ®Google Scholar
• Lee JH, Chan JL, Sourlas E, et al. Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy. J Clin Endocrinol Metab. 2006;91:2605–2611.
   PubMed Web of Science ®Google Scholar
• Fredriksen J, Ueland T, Dyrøy E, et al. Lipid-lowering and anti-inflammatory effects of tetradecylthioacetic acid in HIV-infected patients on highly active antiretroviral therapy. Eur J Clin Invest. 2004;34:709–715.
   PubMed Web of Science ®Google Scholar
• Hadigan C, Liebau J, Torriani M, et al. Improved triglycerides and insulin sensitivity with 3 months of acipimox in human immunodeficiency virus-infected patients with hypertriglyceridemia. J Clin Endocrinol Metab. 2006;91:4438–4444.
   PubMed Web of Science ®Google Scholar
• Keithley JK, Swanson B, Sha BE, et al. A pilot study of the safety and efficacy of cholestin in treating HIV-related dyslipidemia. Nutrition. 2002;18:201–204.
   PubMed Web of Science ®Google Scholar
• Loignon M, Toma E. L-Carnitine for the treatment of highly active antiretroviral therapy-related hypertriglyceridemia in HIV-infected adults. AIDS. 2001;15:1194–1195.
   PubMed Web of Science ®Google Scholar
• Triant VA, Lee H, Hadigan C, et al. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007;92:2506–2512.
   PubMed Web of Science ®Google Scholar
• Butt AA, McGinnis K, Rodriguez-Barradas MC, et al. HIV infection and the risk of diabetes mellitus. AIDS. 2009;23:1227–1234.
   PubMed Web of Science ®Google Scholar
• Hadigan C, Rabe J, Grinspoon S. Sustained benefits of metformin therapy on markers of cardiovascular risk in human immunodeficiency virus-infected patients with fat redistribution and insulin resistance. J Clin Endocrinol Metab. 2002;87:4611–4615.
   PubMed Web of Science ®Google Scholar
• Van Wijk JP, De Koning EJ, Cabezas MC, et al. Comparison of rosiglitazone and metformin for treating HIV lipodystrophy: a randomized trial. Ann Intern Med. 2005;143:337–346.
   PubMed Web of Science ®Google Scholar
• Lamanna C, Monami M, Marchionni N, et al. Effect of metformin on cardiovascular events and mortality: a meta‐analysis of randomized clinical trials. Diabetes Obes Metab. 2011;13:221–228.
   PubMed Web of Science ®Google Scholar
• Hadigan C, Corcoran C, Basgoz N, et al. Metformin in the treatment of HIV lipodystrophy syndrome: a randomized controlled trial. JAMA. 2000;284:472–477.
   PubMed Web of Science ®Google Scholar
• Mannucci E, Monami M, Lamanna C, et al. Pioglitazone and cardiovascular risk. A comprehensive meta‐analysis of randomized clinical trials. Diabetes Obes Metab. 2008;10:1221–1238.
   PubMed Web of Science ®Google Scholar
• Deeg MA, Buse JB, Goldberg RB, et al. Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2007;30:2458–gg64.
   PubMed Web of Science ®Google Scholar
• Tungsiripat M, El Bejjani D, Rizk N, et al. Rosiglitazone improves lipoatrophy in patients receiving thymidine-sparing regimens. AIDS. 2010;24:1291–1298.
   PubMed Web of Science ®Google Scholar
• Lewis JD, Ferrara A, Peng T, et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care 2011; 34: 916–922.
   PubMed Web of Science ®Google Scholar
• Schernthaner G, Currie CJ, Schernthaner G-H. Do we still need pioglitazone for the treatment of type 2 diabetes? A risk-benefit critique in 2013. Diabetes Care. 2013;36(suppl. 2):S155–S161.
   PubMed Web of Science ®Google Scholar
• Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS. 2006;20:2165–2174.
   PubMed Web of Science ®Google Scholar
• Ross AC, Hileman CO, Brown TT, et al. Bone effects of rosiglitazone in HIV-infected patients with lipoatrophy. HIV Clin Trials. 2012;13:212–221.
   PubMed Web of Science ®Google Scholar
• Steven E, Nissen MD, Kathy Wolski MPH. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457–2471.
   PubMed Web of Science ®Google Scholar
• Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696–1705.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Byetta safety update for healthcare professionals. [cited 2015 Nov 18]. Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm190406.htm.
   Google Scholar
• Patil HR, Al Badarin FJ, Al Shami HA, et al. Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus. Am J Cardiol. 2012;110:826–833.
   PubMed Web of Science ®Google Scholar
• White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369:1327–1335.
   PubMed Web of Science ®Google Scholar
• Best C, Struthers H, Laciny E, et al. Sitagliptin reduces inflammation and chronic immune cell activation in HIV+ adults with impaired glucose tolerance. J Clin Endocrinol Metab. 2015;100:2621–2629.
   PubMed Web of Science ®Google Scholar
• Neal B, Perkovic V, De Zeeuw D, et al. Rationale, design, and baseline characteristics of the canagliflozin cardiovascular assessment study (CANVAS)—a randomized placebo-controlled trial. Am Heart J. 2013;166:217–223.
   PubMed Web of Science ®Google Scholar
• Home P, Lagarenne P. Combined randomised controlled trial experience of malignancies in studies using insulin glargine. Diabetologia. 2009;52:2499–2506.
   PubMed Web of Science ®Google Scholar
• Feigenbaum K, Longstaff L. Management of the metabolic syndrome in patients with human immunodeficiency virus. Diabetes Educ. 2010;36:457–464.
   PubMed Web of Science ®Google Scholar
• Krishnan S, Schouten JT, Atkinson B, et al. Metabolic syndrome before and after initiation of antiretroviral therapy in treatment-naive HIV-infected individuals. J Acquir Immune Defic Syndr. 2012;61:381–389.
   PubMed Web of Science ®Google Scholar
• Tebas P. Insulin resistance and diabetes mellitus associated with antiretroviral use in HIV-infected patients: pathogenesis, prevention, and treatment options. J Acquir Immune Defic Syndr. 2008;49(Suppl 2):S86–S92.
   PubMed Web of Science ®Google Scholar
• Jacobson DL, Tang AM, Spiegelman D, et al. Incidence of metabolic syndrome in a cohort of HIV-infected adults and prevalence relative to the US population (National Health and Nutrition Examination Survey). J Acquir Immune Defic Syndr. 2006;43:458–466.
   PubMed Web of Science ®Google Scholar
• Jericó C, Knobel H, Montero M, et al. Metabolic syndrome among HIV-infected patients: prevalence, characteristics, and related factors. Diabetes Care. 2005;28:132–137.
   PubMed Web of Science ®Google Scholar
• Sobieszczyk ME, Hoover DR, Anastos K, et al. Prevalence and predictors of metabolic syndrome among HIV-infected and HIV-uninfected women in the Women’s Interagency HIV Study. J Acquir Immune Defic Syndr. 2008;48:272–280.
   PubMed Web of Science ®Google Scholar
• Norris A, Dreher HM. Lipodystrophy syndrome: the morphologic and metabolic effects of antiretroviral therapy in HIV infection. J Assoc Nurses AIDS Care. 2004;15:46–64.
   PubMed Web of Science ®Google Scholar
• Robinson FP, Quinn LT, Rimmer JH. Effects of high-intensity endurance and resistance exercise on HIV metabolic abnormalities: a pilot study. Bio Res Nurs. 2007;8:177–185.
   PubMed Web of Science ®Google Scholar
• Fitch KV, Anderson EJ, Hubbard JL, et al. Effects of a lifestyle modification program in HIV-infected patients with the metabolic syndrome. AIDS. 2006;20:1843–1850.
   PubMed Web of Science ®Google Scholar
• National Institutes of Health (NIH). DHHS panel on adult and adolescent antiretroviral treatment guidelines. [cited 2009 Apr 14]. Available from: http://www.aidsinfo.nih.gov.
   Google Scholar
• Fernandez ML. The metabolic syndrome. Nutr Rev. 2007;65:S30–S34.
   PubMed Web of Science ®Google Scholar
• Larson R, Capili B, Eckert-Norton M, et al. Disorders of glucose metabolism in the context of human immunodeficiency virus infection. J Aanp. 2006;18:92–103.
   Google Scholar
• Stein JH, Hadigan CM, Brown TT, et al. Prevention strategies for cardiovascular disease in HIV-infected patients. Circulation. 2008;118:e54–e60.
   PubMedGoogle Scholar
• Thomson Reuters. Micromedex. [cited 2016 Dec 14]. Available from: http://www.thomsonhc. com/hcs/librarian.
   Google Scholar
• Van Wijk JP, Cabezas MC. Hypertriglyceridemia, metabolic syndrome, and cardiovascular disease in HIV-infected patients: effects of antiretroviral therapy and adipose tissue distribution. Int J Vasc Med. 2012;2012:201027.
   PubMedGoogle Scholar
• Nduka CU, Stranges S, Sarki AM, et al. Evidence of increased blood pressure and hypertension risk among people living with HIV on antiretroviral therapy: a systematic review with meta-analysis. J Hum Hypertens. 2015 Oct 8. [Epub ahead of print]. doi:10.1038/jhh.2015.97.
   PubMed Web of Science ®Google Scholar
• Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in obesity among US adults, 1999–2008. JAMA. 2010;303:235–241.
   PubMed Web of Science ®Google Scholar
• Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348:1625–1638.
   PubMed Web of Science ®Google Scholar
• Bogers RP, Bemelmans WJ, Hoogenveen RT, et al. Association of overweight with increased risk of coronary heart disease partly independent of blood pressure and cholesterol levels a meta-analysis of 21 cohort studies including more than 300 000 persons. Arch Intern Med. 2007;167:1720–1728.
   PubMed Web of Science ®Google Scholar
• Amorosa V, Synnestvedt M, Gross R, et al. A tale of 2 epidemics: the intersection between obesity and HIV infection in Philadelphia. J Acquir Immune Defic Syndr. 2005;39:557–561.
   PubMed Web of Science ®Google Scholar
• Crum-Cianflone N, Tejidor R, Medina S, et al. Obesity among patients with HIV: the latest epidemic. AIDS Patient Care STDS. 2008;22:925–930.
   PubMed Web of Science ®Google Scholar
• Boodram B, Plankey MW, Cox C, et al. Prevalence and correlates of elevated body mass index among HIV-positive and HIV-negative women in the Women’s Interagency HIV Study. AIDS Patient Care STDS. 2009;23:1009–1016.
   PubMed Web of Science ®Google Scholar
• Tate T, Willig AL, Willig JH, et al. HIV infection and obesity: where did all the wasting go? Antivir Ther. 2012;17:1281–1289.
   PubMed Web of Science ®Google Scholar
• Mateo MG, Gutierrez MM, Vidal F, et al. An update on the pharmacological strategies in the treatment of HIV-1-associated adipose redistribution syndromes. Expert Opinion Pharmacother. 2014;15:1749–1760.
   PubMed Web of Science ®Google Scholar
• Monsueza JJ, Charniota JC, Vittecogb D, et al. HIV-associated vascular diseases: structural and functional changes, clinical implications. Int J Cardiol. 2009;133:293–306.
   PubMed Web of Science ®Google Scholar
• Aberg JA, Gallant JE, Ghanem KG, et al. Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV medicine association of the infectious diseases society of America. Clin Infect Dis. 2014;58:1–10.
   PubMed Web of Science ®Google Scholar
• Tornero C, Ventura A, Mafe M, et al. Aspirin is indicated for primary prevention of cardiovascular events in HIV-infected patients. J Acquir Immune Defic Syndr. 2010;54:560.
   PubMed Web of Science ®Google Scholar